BCT — Briacell Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$26.93m
- CA$19.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.4 | ||
| Price to Tang. Book | 5.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -661.02% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jul | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Directors
- Jamieson Bondarenko CHM
- William Williams PRE
- Gadi Levin CFO (48)
- Marc Lustig DRC (47)
- Vaughn Embro-Pantalony IND
- Jane Gross IND (64)
- Martin Schmieg IND
- Rebecca Taub IND (69)
- Last Annual
- July 31st, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- July 26th, 2006
- Public Since
- October 12th, 2006
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 3,709,440
- Address
- Suite 300 - Bellevue Centre, WEST VANCOUVER, V7T 2X1
- Web
- https://briacell.com/
- Phone
- +1 6049211810
- Auditors
- MNP LLP
Upcoming Events for BCT
Q4 2025 Briacell Therapeutics Corp Earnings Release
Similar to BCT
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
Eupraxia Pharmaceuticals
Toronto Stock Exchange
FAQ
What is the Briacell Therapeutics share price?
As of Today at 19:41 UTC, shares in Briacell Therapeutics are trading at CA$7.26. This share price information is delayed by 15 minutes.
How has the Briacell Therapeutics share price performed this year?
Shares in Briacell Therapeutics last closed at CA$7.26 and the price had moved by -83.92% over the past 365 days. In terms of relative price strength the Briacell Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -85.7% over the past year.
What are the analyst and broker recommendations for Briacell Therapeutics?
The overall consensus recommendation for Briacell Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Briacell Therapeutics dividend yield?
Briacell Therapeutics does not currently pay a dividend.
Does Briacell Therapeutics pay a dividend?
Briacell Therapeutics does not currently pay a dividend.
When does Briacell Therapeutics next pay dividends?
Briacell Therapeutics does not currently pay a dividend.
How do I buy Briacell Therapeutics shares?
To buy shares in Briacell Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Briacell Therapeutics?
As of the previous close price of CA$7.26, shares in Briacell Therapeutics had a market capitalisation of CA$26.93m.
Where are Briacell Therapeutics shares listed?
Here are the trading details for Briacell Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: BCT
What kind of share is Briacell Therapeutics?
Based on an overall assessment of its quality, value and momentum Briacell Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Briacell Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Briacell Therapeutics is CA$20.39. That is 180.89% above the last closing price of CA$7.26.
Analysts covering Briacell Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.14 for the next financial year.
Find out moreWhat is the trend in the Briacell Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Briacell Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -59.9%.
As of the last closing price of CA$7.26, shares in Briacell Therapeutics were trading -40.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Briacell Therapeutics PE Ratio?
The Briacell Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$7.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Briacell Therapeutics?
Briacell Therapeutics' management team is headed by:
- Jamieson Bondarenko - CHM
- William Williams - PRE
- Gadi Levin - CFO
- Marc Lustig - DRC
- Vaughn Embro-Pantalony - IND
- Jane Gross - IND
- Martin Schmieg - IND
- Rebecca Taub - IND